

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re the application of: Dana M. Fowlkes, *et al.*

Serial No.: 09/258600

Filed: February 26, 1999

For: *Yeast Cells Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor*

Attorney Docket No.: CPI-012CP4DV

Group Art Unit: 1643

Examiner: Not Assigned

TECH CENTER 1600/2900

RECEIVED

Office of Initial Patent Examination Customer Service Center
Commissioner for Patents
Washington, DC 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Office of Initial Patent Examination Customer Service Center, Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

December 13, 2002

Date of Signature and of Mail Deposit

By:

Hathaway Pease, Esq., Reg. No. 46,488

ASSOCIATE POWER OF ATTORNEY

Sir:

The undersigned attorney has the power of attorney in the subject application. He hereby grants an associate power to:



Hathaway Pease, Esq.
Registration No. 46,488
Lahive & Cockfield, LLP
60 State Street
Boston, MA 02109

Please continue to forward all written and telephonic communications to Giulio A. DeConti, Jr. at the address and telephone number listed below.

Respectfully submitted,

Peter C. Lauro, Esq.
Registration No. 32,360
Attorney for Applicants

LAHIVE & COCKFIELD, LLP
60 State Street
Boston, MA 02109
Tel. (617) 227-7400



APRIL 19, 2002

PTAS

Chief Financial Officer and Chief Administrative Officer
Washington, DC 20231
www.uspto.gov

LAHIVE & COCKFIELD, LLP
PETER C. LAURO, ESQ.
28 STATE STREET
BOSTON, MA 02109



101994847A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/11/2002

REEL/FRAME: 012598/0490
NUMBER OF PAGES: 10

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

CADUS PHARMACEUTICAL CORPORATION

DOC DATE: 12/18/2001

ASSIGNEE:

CADUS TECHNOLOGIES, INC.
767 FIFTH AVENUE
NEW YORK, NEW YORK 10153

SERIAL NUMBER: 09309196
PATENT NUMBER:

FILING DATE: 05/10/1999
ISSUE DATE:

SERIAL NUMBER: 09286166
PATENT NUMBER:

FILING DATE: 04/05/1999
ISSUE DATE:

SERIAL NUMBER: 09143246
PATENT NUMBER:

FILING DATE: 08/28/1998
ISSUE DATE:

SERIAL NUMBER: 09258600
PATENT NUMBER:

FILING DATE: 02/26/1999
ISSUE DATE:

SERIAL NUMBER: 09747774
PATENT NUMBER:

FILING DATE: 12/21/2000
ISSUE DATE:

SERIAL NUMBER: 09953354
PATENT NUMBER:

FILING DATE: 09/13/2001
ISSUE DATE:

SERIAL NUMBER: 08946298
PATENT NUMBER:

FILING DATE: 10/07/1997
ISSUE DATE:

SERIAL NUMBER: 09201396
PATENT NUMBER:

FILING DATE: 11/30/1998
ISSUE DATE:

SERIAL NUMBER: 09581861
PATENT NUMBER:

FILING DATE: 03/05/2001
ISSUE DATE:

SERIAL NUMBER: 09241888
PATENT NUMBER:

FILING DATE: 02/01/1999
ISSUE DATE:

SERIAL NUMBER: 09658765
PATENT NUMBER:

FILING DATE: 09/08/2000
ISSUE DATE:

SERIAL NUMBER: 09592010
PATENT NUMBER:

FILING DATE: 06/12/2000
ISSUE DATE:

SERIAL NUMBER: 09378046
PATENT NUMBER:

FILING DATE: 08/20/1999
ISSUE DATE:

SERIAL NUMBER: 09305923
PATENT NUMBER: 6355473

FILING DATE: 05/05/1999
ISSUE DATE: 03/12/2002

SERIAL NUMBER: 09362286
PATENT NUMBER:

FILING DATE: 07/27/1999
ISSUE DATE:

SERIAL NUMBER: 09527998
PATENT NUMBER:

FILING DATE: 03/17/2000
ISSUE DATE:

SERIAL NUMBER: 08322137
PATENT NUMBER: 6100042

FILING DATE: 10/13/1994
ISSUE DATE: 08/08/2000

SERIAL NUMBER: 08461598
PATENT NUMBER: 5876951

FILING DATE: 06/05/1995
ISSUE DATE: 03/02/1999

SERIAL NUMBER: 08464531
PATENT NUMBER: 5789184

FILING DATE: 06/05/1995
ISSUE DATE: 08/04/1998

SERIAL NUMBER: 08582333
PATENT NUMBER: 6255059

FILING DATE: 01/17/1996
ISSUE DATE: 07/03/2001

SERIAL NUMBER: 08732218
PATENT NUMBER: 6001553

FILING DATE: 01/14/1997
ISSUE DATE: 12/14/1999

SERIAL NUMBER: 08936632
PATENT NUMBER: 6159705

FILING DATE: 09/24/1997
ISSUE DATE: 12/12/2000

012598/0490 PAGE 3

SERIAL NUMBER: 09042853
PATENT NUMBER: 6251065

FILING DATE: 03/17/1998
ISSUE DATE: 06/26/2001


KIMBERLY WHITE, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

FORM PTO-1595

(Rev. 3/01)

OMB No. 0651-0027 (exp. 5/31/2002)

02-27-2002



SHEET

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Tab settings ⇄⇄⇄▽

101994847

▽CPI-000

▽

▽

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party:

Cadus Pharmaceutical Corporation

2.11.02

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party:

Name: Cadus Technologies, Inc.

Internal Address: _____

Street Address: 767 Fifth AvenueCity: New York State: NY ZIP: 10153Additional name(s) & address(es) attached? ☐ Yes ☒ No

3. Nature of conveyance

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ Other _____Execution Date: December 18, 2001

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

1. 08/322,137 (6,100,042)2. 09/309,196

B. Patent No.(s)

Additional numbers attached? ☒ Yes ☐ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Peter C. Lauro, Esq.Internal Address: Lahive & Cockfield, LLPStreet Address: 28 State StreetCity: Boston State: MA ZIP: 02109

6. Total number of applications and patents involved:

23

7. Total fee (37 CFR 3.41).....\$ \$920.00☒ Enclosed☐ Authorized to be charged to deposit account

8. Deposit account number:

12-0080

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Peter C. Lauro, Esq.

Name of Person Signing

Signature

January 11, 2002
 Date

Total number of pages including cover sheet, attachments, and document:

10

02/26/2002 BYRNE 00000088 08322137

01 FC:581

Mail documents to be recorded with required cover sheet information to:
92000-10 Assignment, Director - U.S. Patent and Trademark Office
Washington, D.C. 20231



Additional Application/Patent Numbers
CPI-000

A. Patent Application/Patent Numbers

3. 09/286,166
4. 09/143,246
5. 08/461,598 (5,876,951)
6. 09/258,600
7. 08/464,531 (5,789,184)
8. 08/582,333 (6,255,059)
9. 09/747,774
10. 09/953,354
11. 08/946,298
12. 09/201,396
13. 09/581,861
14. 08/732,218 (6,001,553)
15. 08/936,632 (6,159,705)
16. 09/241,888
17. 09/658,765
18. 09/592,010
19. 09/378,046
20. 09/305,923
21. 09/426,332 (6,251,605B1)
22. 09/362,286
23. 09/527,998


GENERAL ASSIGNMENT OF PATENT RIGHTS

WHEREAS, Cadus Pharmaceutical Corporation, a corporation with a place of business at 767 Fifth Avenue, New York, NY 10153 (hereinafter "ASSIGNOR"), is the owner of the entire right, title and interest in and to the patents and patent applications identified in Appendix A hereto;


WHEREAS, ASSIGNOR desires to sell, convey, transfer, assign, and deliver its entire interest in the patents and patent applications identified in Appendix A to its wholly-owned subsidiary, Cadus Technologies, Inc., a Delaware corporation ("ASSIGNEE");

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, ASSIGNOR, does hereby sell, convey, transfer, assign and deliver to ASSIGNEE the full and exclusive right, title and interest in and to the patents and patent applications identified in Appendix A hereto and any divisional, continuing, reissue or other applications based in whole or in part thereon. This Patent Assignment includes the right to pursue all claims for damages by reason of past infringement of any and all patents listed in Appendix A hereto with the right to sue for, and collect the same for its own use and for the use of its successors, assigns or other legal representatives as fully and entirely as the same would have been enjoyed by ASSIGNOR, if this assignment had not been made.

CADUS PHARMACEUTICAL CORPORATION

By 
Russell D. Glass, President

Sworn to before me and subscribed in my presence this 18th day of December, 2001.


Notary Public

PAUL WOLFSON
NOTARY PUBLIC, State of New York
No. 01WO5024198
Qualified in Westchester County
Commission Expires March 7, 2002

Appendix A to General Assignment of Patent Rights



I. U.S. Applications/Patents

Attorney Docket No.	Serial No./ Patent No.	Title	Filing Date/ Issue Date/ Expiration Date	Status
CPI-012CP3	08/322,137 6,100,042	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	10/13/94 8/8/00 8/8/17	ISSUED
CPI-012CP3CN	09/309,196	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	5/10/99	PENDING
CPI-012CP4BCN	09/286,166	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	4/5/99	PENDING
CPI-012CP4DVCPA	09/143,246	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	8/28/98 (CPA filed 6/28/00)	PENDING
CPI-012CP4C	08/461,598 5,876,951	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	6/5/95 3/2/99 3/2/16	ISSUED
CPI-012CP4DV	09/258,600	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	2/26/99	PENDING
CPI-012CP4D	08/464,531 5,789,184	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	6/5/95 8/4/98 8/4/15	ISSUED
CPI-012CP5	08/582,333 6,255,059	Methods and Composition for Identifying Receptor Effectors	1/17/96 7/03/01 8/8/17	ISSUED
CPI-012CP5DV	09/747,774	Methods and Composition for Identifying Receptor Effectors	12/21/00	PENDING

REC'D

JAN 1

TECH CENTER 1600

U.S. Applications/Patents (cont'd)

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing/ Issue Date/ Expiration Date</i>	<i>Status</i>
C'PI-012C'P7C'PAC'N	09/953,354	Methods and Composition for Identifying Receptor Effectors	9/13/01	PENDING
C'PI-012C'P8C'PA	08/946,298	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/07/97	PENDING
C'PI-012C'P9	09/201,396	Methods and Compositions for Identifying Receptor Effectors	11/30/98	PENDING
C'PI-012C'8US	09/581,861	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
C'PI-014US	08/732,218 6,001,553	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95 12/14/99	ISSUED
C'PI-031C'P2	08/936,632 6,159,705	Methods and Compositions for Identifying Receptor Effectors	9/24/97 12/12/00 9/24/16	ISSUED

U.S. Applications/Patents (cont'd)

Attorney Docket No.	Serial No./ Patent No.	Title	Filing Date/ Issue Date/ Expiration Date	Status
CP1-102	09/241,888	Cell Based Signal Generation	2/1/99	PENDING
CP1-122	09/658,765	Yeast Alpha Agglutinins and Use Thereof as Indicators of Activation of the Yeast Pheromone Response Pathway	9/08/00	PENDING
CP1-123	09/592,010	Mating Factor α System for Detection of a Functional Interaction Between A Compound and a Cellular Receptor	6/12/00	PENDING
CP1-088	09/378,046	Cells Having Amplified Signal Transduction Pathway Responses and Uses Therefor	8/30/99	PENDING
CP1-091	09/305,923	Yeast Cells Having Mutations in STP22 and Uses Therefor	5/5/99	PENDING
CP1-096	09/426,332 6,251,605B1	Yeast Cells Having Mutations in CAV1 and Uses Therefor	10/25/99 6/26/01 10/25/19	ISSUED

U.S. Applications/Parents (cont'd)

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing Date/ Issue Date/ Expiration Date</i>	<i>Status</i>
CPI-099	09 362,286	Expression of G Protein Coupled Receptors with Altered Ligand Binding and/or Coupling Properties	7/27/99	PENDING
CPI-110	09 527,998	Methods for Identifying Target G Protein-Coupled Receptors Using Hidden Markoff Models	3/17/00	PENDING

II. International Applications/Patents

Attorney Docket No.	Serial No./ Patent No.	Title	Filing Date/ Expiration Date/ Issue Date	Status
CPI-012CPAU	64909/94 685103	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94 4/30/98 3/23/14	GRANTED
CPI-012CPAUDV2	71696/00	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	11/16/00	PENDING
CPI-012CPCA	2,158,274 2,158,274	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94 5/30/00 3/23/14	GRANTED
CPI-012CPEP	94912292.3 0692025	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94 10/17/01 3/23/14	GRANTED Registration pending for AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL and SE
CPI-012CPEPDV	98202997.7	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	9/8/98	PENDING
CPI-012CPJP	06-522167	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94	PENDING
CPI-012C8AU	97911/98	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
CPI-012C8CA	2305204	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING

CPI-012C8EP	98 95 2143.0	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
-------------	--------------	---	---------	---------

International Applications/Patents (cont'd)

Attorney Docket No.	Serial No./ Patent No.	Title	Filing Date/ Issue Date/ Expiration Date	Status
CPI-012C8JP	2000-515008	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
CPI-014AU	26354/95 702075	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95 5/27/99 4/26/15	GRANTED
CPI-014CA	2,188,950 2,188,950	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95 7/03/01 4/26/15	GRANTED
CPI-014JP	528355/95	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95	PENDING
CPI-031C2AU	45930/97 733,007	Methods and Compositions for Identifying Receptor Effectors	9/24/97 8/16/01 9/24/17	GRANTED
CPI-031C2CA	2,266,543	Methods and Compositions for Identifying Receptor Effectors	9/24/97	PENDING
CPI-031C2EP	97 94 4430.4	Methods and Compositions for Identifying Receptor Effectors	9/24/97	PENDING
CPI-031C2JP	10-515880	Methods and Compositions for Identifying Receptor Effectors	9/24/97	PENDING

Two letter country code: AT = Austria; AU = Australia; BE = Belgium; CH = Switzerland; DE = Germany; DK = Denmark; EP = Europe (European Patent Convention); ES = Spain; FR = France; GB = Great Britain; GR = Greece; IE = Ireland; IT = Italy; JP = Japan; LU = Luxembourg; NL = Netherlands; SE = Sweden